Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) - Pipeline Review, H1 2016

Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) - Pipeline Review, H1 2016
Published Jun 15, 2016
69 pages — Published Jun 15, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) - Pipeline Review, H1 2016, provides in depth analysis on Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) targeted pipeline therapeutics.

The report provides comprehensive information on the Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen)
- The report reviews Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) targeted therapeutics and enlists all their major and minor projects
- The report assesses Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain compe

  
Source:
Document ID
GMDHC0053TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents24
  List of Tables51
  List of Figures51
Introduction61
  Global Markets Direct Report Coverage61
Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) Overview71
Therapeutics Development84
  Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) Products under Development by Stage of Development81
  Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) Products under Development by Therapy Area91
  Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) Products under Development by Indication102
Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) Pipeline Products Glance122
  Late Stage Products121
  Early Stage Products131
Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) Products under Development by Companies144
Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) Products under Development by Universities/Institutes182
Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) Therapeutics Assessment207
  Assessment by Monotherapy/Combination Products201
  Assessment by Mechanism of Action212
  Assessment by Route of Administration232
  Assessment by Molecule Type252
Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) Companies Involved in Therapeutics Development278
  Amgen Inc.271
  AnGes MG, Inc.281
  Kringle Pharma, Inc.291
  M3 Biotechnology, Inc.301
  Minerva Biotechnologies Corporation311
  Molecular Partners AG321
  ViroMed Co., Ltd.331
  Yooyoung Pharmaceutical Co., Ltd.341
Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) Drug Profiles3519
  beperminogene perplasmid Drug Profile355
  Gene Therapy to Antagonize HGF for Rheumatoid Arthritis and Hepatocellular Carcinoma Drug Profile401
  MM-201 Drug Profile411
  Monoclonal Antibodies to Inhibit Hepatocyte Growth Factor for Metastatic Cancer Drug Profile421
  MP-0250 Drug Profile431
  NK-4 Drug Profile441
  rilotumumab Drug Profile452
  SL-012 Drug Profile471
  SL-186 Drug Profile481
  SL-188 Drug Profile491
  VM-202 Drug Profile503
  YYB-101 Drug Profile531
Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) Dormant Projects542
Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) Discontinued Products561
Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) Featured News &Press Releases5711
  May 18, 2016: VM BioPharma Announces FDA Fast Track Designation Granted for Investigational Gene Therapy VM202 for Patients with Amyotrophic Lateral Sclerosis571
  Jan 22, 2016: ViroMed Publishes Results from Critical Limb Ischemia Phase II Clinical Study571
  Jan 08, 2016: Molecular Partners to Conduct Phase II Trial of MP0250, a Multi-DARPin Targeting VEGF and HGF, in Multiple Myeloma581
  Nov 07, 2015: Research Presented at AACR-NCI-EORTC Shows Good Tolerability and Sustained Systemic Exposure of MP0250, a Multi-DARPin Targeting VEGF and HGF, in Patients with Advanced Cancer591
  Oct 27, 2015: First clinical data of multi-DARPin MP0250 to be presented at the AACR-NCI-EORTC oncology conference601
  Sep 01, 2015: US FDA Approves Initiation of ViroMed's VM202 for Phase III Clinical Study of Chronic Non-Healing Ischemic Diabetic Foot Ulcer611
  Aug 12, 2015: Patient Enrollment Begins in Europe in the Global Phase III Clinical Trial of HGF Gene Therapy for Critical Limb Ischemia621
  Mar 06, 2015: ViroMed dba VM BioPharma: A Phase II Study Done at Northwestern Hospital Shows Potential Relief for Diabetics with Painful Condition622
  Nov 24, 2014: Amgen Announces Termination Of All Amgen-Sponsored Clinical Studies Of Rilotumumab In Advanced Gastric Cancer641
  Nov 13, 2014: First Patient Dosed in Global Phase III Clinical Trials of HGF Plasmid for Critical Limb Ischemia641
  Oct 29, 2014: AnGes to Start Global Phase III Clinical Trials of HGF Gene Therapy for Critical Limb Ischemia in Europe651
  Oct 16, 2014: First Patient Dosed in Physician-led Study of HGF Gene Therapy in Japan651
  Oct 05, 2014: AnGes Starts Global Phase III Clinical Trials of Collategene for Critical Limb Ischemia661
  Jun 16, 2014: Amgen Joins The National Cancer Institute And Research Partners To Help Accelerate Development Of Personalized Treatment Approaches For Squamous Cell Lung Cancer661
  Jun 12, 2014: AnGes Signs an Agreement with Quintiles for the Global Phase III Trial of Collategene, a Gene Therapy Product for Critical Limb Ischemia671
Appendix682
  Methodology681
  Coverage681
  Secondary Research681
  Primary Research681
  Expert Panel Validation681
  Contact Us681
  Disclaimer691

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) - Pipeline Review, H1 2016" Jun 15, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Hepatocyte-Growth-Factor-Hepatopoietin-A-or-Lung-Fibroblast-Derived-Mitogen-Pipeline-Review-H1-2016-2088-15960>
  
APA:
Global Markets Direct - Market Research. (2016). Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) - Pipeline Review, H1 2016 Jun 15, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Hepatocyte-Growth-Factor-Hepatopoietin-A-or-Lung-Fibroblast-Derived-Mitogen-Pipeline-Review-H1-2016-2088-15960>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.